Michel Sadelain
Overview
Explore the profile of Michel Sadelain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
245
Citations
26200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahid S, Prockop S, Flynn G, Mauguen A, White C, Bieler J, et al.
Blood Adv
. 2025 Feb;
PMID: 39908482
Despite clinical benefit with the use of CAR T-cells, the need to manufacture patient-specific products severely limits the clinical utility of this therapy. To overcome this barrier, we developed an...
2.
Perica K, Jain N, Scordo M, Patel R, Eren O, Patel U, et al.
N Engl J Med
. 2025 Feb;
392(6):577-583.
PMID: 39908432
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of...
3.
Perica K, Kotchetkov I, Mansilla-Soto J, Ehrich F, Herrera K, Shi Y, et al.
Nature
. 2025 Jan;
PMID: 39884316
Autologous chimeric antigen receptor (CAR) T cells are a genetically engineered therapy that is highly effective against B cell malignancies and multiple myeloma. However, the length and cost of personalized...
4.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
J Clin Oncol
. 2025 Jan;
:JCO2402424.
PMID: 39883889
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that...
5.
Haubner S, Subklewe M, Sadelain M
Blood
. 2024 Dec;
145(11):1113-1125.
PMID: 39630061
Acute myeloid leukemia (AML) remains a dismal disease with poor prognosis, particularly in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) therapy has yielded remarkable clinical results in other leukemias...
6.
Saetersmoen M, Kotchetkov I, Torralba-Raga L, Mansilla-Soto J, Sohlberg E, Krokeide S, et al.
Med
. 2024 Oct;
6(2):100521.
PMID: 39423821
Background: Human leukocyte antigen (HLA)-E is overexpressed by a large proportion of solid tumors, including malignant glioblastoma, and acts as a major checkpoint for NKG2A CD8 T cells and natural...
7.
8.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
Res Sq
. 2024 Jul;
PMID: 39011120
We designed a CD19-targeted CAR comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3z and 4-1BB/CD3z CARs. Here we report the first-in-human, phase 1 clinical...
9.
Hammer Q, Perica K, Mbofung R, van Ooijen H, Martin K, Momayyezi P, et al.
Cell Stem Cell
. 2024 Jul;
31(9):1376-1386.e8.
PMID: 38981470
Allogeneic cellular immunotherapies hold promise for broad clinical implementation but face limitations due to potential rejection of donor cells by the host immune system. Silencing of beta-2 microglobulin (B2M) expression...
10.
Shi Y, Kotchetkov I, Dobrin A, Hanina S, Rajasekhar V, Healey J, et al.
Mol Ther
. 2024 May;
32(7):2393-2405.
PMID: 38720457
The tumor microenvironment presents many obstacles to effective chimeric antigen receptor (CAR) T cell therapy, including glucose competition from tumor and myeloid cells. Using mouse models of acute lymphoblastic leukemia...